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The lgh complex is on the murine 12th chromosome and contains the genes 
(Igh-C) that encode the constant (C) portion of/~, 6, 3', a, and e immunoglobulin 
(Ig)  heavy chains  together  with J,  D,  and  V region  genes  that  encode  their 
corresponding variable (V) regions (1-3).  In addition to these Igh genes, there 
are  several  other  linked  genes,  some  of which  may play  a  role  in  immune 
reactivity. For example, a  series of antigens have been  described: Tsu, Tind, 
Tthy, and Tpre,  which are controlled by genes that map telomeric to the lgh 
locus (reference 4, and R. Riblet, E.  Eicher, and B. Taylor, unpublished data). 
These antigens are limited in their tissue expression to T  cell subsets and have 
been detected on T  cell factors that have immunoregulatory activity (5-7).  Lyb- 
7 is an antigenic determinant controlled by a gene linked to the lgh-V side of the 
complex and is selectively expressed on a  B lymphocyte subset (8).  In contrast, 
the lgh-linked  minor histocompatibility H(Igh) (9) and prealbumin (Pre-1) genes 
(10) presumably encode molecules that are unrelated to the immune system. 
We have previously observed that immunization of C.B-20 (Igh  b) mice with Igh 
congenic spleen or surface (s) Ig  + tumor cells of BALB/c (Igh  a) origin elicits both 
tumor rejection and  the  generation of cytotoxic T  lymphocytes (CTL)  1 that 
recognize an antigen controlled by an lgh-linked  gene (1 1,  12).  We term  this 
gene H-40. Surprisingly, the expression of the CTL target antigen is coincident 
with the expression of sIg. While the possibility exists that the antigen is in fact 
a sIg determinant, in this report we demonstrate that the gene controlling the 
expression of this antigen maps away from the Igh locus, in the region of Pre-l. 
Besides providing information on the genetics of H-40, we also present further 
evidence to indicate that the expression of this antigen requires the presence of 
sIg. 
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Materials and  Methods 
Mice.  Mice  were  bred  at  the  animal  colonies of The  University of Texas  Health 
Science Center at Dallas (UTHSCD) and the Institute for Cancer Research (ICR). Some 
mice were kindly provided by Dr. M. Potter of the National Institutes of Health (Contract 
No.  1-CB-94326).  Igh recombinant strains were bred at ICR for the analysis of the lgh 
locus (nomenclature as in reference 3) and nearby regions of chromosome 12 (references 
4,  13, and R. Riblet, unpublished). 
Media.  Media used for culture was RPMI 1640 supplemented with 2-mercaptoethanol 
and 10% fetal calf serum (FCS). 
Antisera.  Antibodies against allotypes of IgD (Igh-5" or Igh-5  b molecules) were mon- 
oclones obtained from the Salk Institute. The antibodies were affinity purified and utilized 
along with a fluoresceinated rabbit anti-mouse ~" chain antibody (12) for the cell sorting 
experiments. Rabbit antibodies against the BCL~ idiotype and/~ chains have been previ- 
ously described (14) and were used together with fluoresceinated goat anti-rabbit sera for 
the analysis of sIg on the subclones of BCLI. Fluoresceinated (Fab)'2 rabbit anti-mouse Ig 
was used to analyze sIg on B lymphoma cells.  The latter two fluoresceinated reagents 
were  purchased  from  Cappel  Laboratories  (West  Chester,  PA).  Anti-H-2  sera  were 
produced by immunizing H-2 congenic strains of mice. 
Fluorescence-activated Cell Sorter  (FACS).  A  FACS  III (Becton-Dickinson,  Palo Alto, 
CA) was used to analyze and sort sigh-5  a positive cells from (C.B-20 x  BALB/c)F1 spleens 
using indirect  immunofluorescence.  Following the sort, >98%  of the positive cells ex- 
pressed sigh-5  a, while >98% of the negatively sorted cells were unstained for this molecule. 
Cytotoxic T  Cell Assay.  This has been described previously (11,  12).  Briefly, C.B-20 
mice were immunized with  3  x  107 BALB/c spleen cells or vice-versa. After 3 wk, the 
mice were sacrificed and their spleen cells were cocultured with irradiated BALB/c cells 
for 5 d  before assay in a  standard 5~Cr release cytotoxicity assay. Data are expressed as 
net isotope release, which equals the percent release of isotope from target cells in the 
presence of sensitized  effector cells -  the  percent  release of isotope from target cells 
cultured  with  control  (nonsensitized)  cells.  When  the  data  were  analyzed  using  CTL 
clones, control release represented the isotope release from target cells cultured in media 
(spontaneous release). 
The competition assay has been previously described (15). Briefly, unlabeled inhibitor 
cells  were  added  to  wells  along  with  labeled  target  cells  and  effector  cells.  Percent 
inhibition of isotope release was calculated as described in the text. 
Generation of CTL Clones.  CTL clones were generated by culturing C.B-20 spleen ceils 
from primed mice with BALB/c splenic stimulator cells for 5 d in bulk culture. The cells 
were harvested and recultured with fresh stimulator cells for 3 d after which the responder 
cells were plated in 96-well plates at several dilutions and cultured in media containing a 
rat concanavalin A (Con A) supernatant. Individual wells were scored for growth after 10 
d  and  positive wells  from plates,  where  the  probability that  each  individual  well  was 
derived from a single cell was >98%, were transferred to 24-well plates. The clones were 
expanded and tested for activity and specificity. 
Target Cells.  Target cells were splenocytes cultured with lipopolysaccharide (LPS; 100 
#g/ml) for 3 d or tumor cells. 
Tumor Cells.  WEHI231, ABE-8, and  PK-3, were kindly provided by Dr.  L.  Lanier 
(University  of  New  Mexico)  and  have  been  described  (16).  A20-056,  M12, 
BALENLM17.1.11.15 and 16, and B17* represent tumors derived by Kim et al. (17) and 
subcloned and provided to us by Drs.  C.  Word and  M.  Kuehl,  University of Virginia 
Medical  School  (18).  Meth  A  tumor  cells  were  kindly  provided  by  Dr.  E.  Stockert, 
Memorial SIoan-Kettering Cancer Institute,  New York, NY.  BCL~ and  BCLlX63 have 
been described previously (19, 20). Four subclones of the in vitro BCL~ tumor line, 3G2, 
3B3-10,  B1.4.23,  and  B1.4.24  were  obtained  by  limiting  dilution  culture  (21).  The 
subclones 3G2 and 3B3 (from which 3B3-10 was further subcloned) have been described 
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Results 
Expression of a  CTL  Target  Antigen  on  Mice  Carrying  Different  Igh  Haplo- 
types.  We have previously shown that  C.B-20  (Igh  b) animals immunized with 
BALB/c  (Igh ~)  splenocytes generate,  when  re-challenged in  vitro,  CTL  that 
recognize a  target antigen, H-40,  controlled by a  gene linked to the Igh locus 
(12).  In order to determine the expression of this antigen in different mouse 
strains, we tested C.B-20 anti-BALB/c effector cells against LPS-activated splenic 
lymphoblasts obtained from a panel of strains bearing different Igh haplotypes. 
Since  the CTL  activity is H-2  a restricted (see below),  non-H-2  a  strains  were 
mated to C.B-20 mice and the H-2  d heterozygotes were tested for the expression 
of the antigen. 
The data in Fig. 1 (A-C) demonstrate that C.B-20 anti-BALB/c CTL lyse LPS- 
activated lymphoblasts from BALB/c (Igh~), C.AL-20  (Ighd), and  C57L  (Igh  ~) 
strains.  In  most  experiments,  the  net  release  from  these  target  cells  ranged 
between  15-40%  at E/T =  100.  In contrast, target cells from strains BAB-14 
(Igh-V  a Igh-Cb), C58 (Igh~), and NZB (Igh e) were not killed. A summary of results 
for the strains  tested is  listed in  Table  I.  All target cells were concomitantly 
tested  for  their  sensitivity  to  lysis  by  anti-H-2  d  CTL  and  were  noted  to  be 
susceptible to lysis (Fig.  1, E-H). 
BALB/c  anti-C.B-20  CTL  were also  analyzed for  their  cytotoxic potential 
against a limited panel of target cells. Although the lytic activity of these effector 
cells was usually much less than that observed for the C.B-20 anti-BALB/c CTL, 
they killed C.B-20, BAB-14, and B10.D2, but not C.AL-20 or NZB targets (see 
(Fig.  1 D;  Fig.  3, A, B, and D; and Table I).  Thus, these results indicate that 
there are at least three alleles, as defined by CTL, for the Ho40 gene. Strains 
with the a  allele include BALB/c,  C57L,  DBA/2,  C.AL-20,  and AKR; strains 
with the b allele include C.B-20 and B 10.D2, and strains with a third and possibly 
null allele include NZB. 
Polymorphism of H-40 as Detected by CTL Activity.  The previous data indicates 
that mice carrying the Igh hapiotypes of a, c, d (with the exception of C58) have 
the same allele for H-40. However, each of these strains could share a common 
epitope while at the same time expressing a  unique specificity, each of which 
would define a  different allele.  To address this  issue,  we  tested  C.B-20  anti- 
BALB/c effector cells against 5~Cr-labeled targets in the presence of unlabeled 
inhibitor cells taken from other antigen-positive strains. 
C.B-20  anti-BALB/c  CTL  lyse  BALB/c  target  cells  and  this  activity  was 
completely blocked  by  the presence of an  excess of unlabeled  BALB/c  LPS 
lymphoblasts, as expected (Fig.  2,  left).  C.AL-20 and DBA/2  target cells were 
killed by the effector cells (Table I and Fig.  1).  Further, when these cells were 
used  as  inhibitors,  they  blocked  the  cytotoxic effect to  the  same  extent  as 
BALB/c  inhibitors.  When  the C.B-20  anti-BALB/c  CTL  were tested  against 
either C.AL-20 (Fig. 2, middle) or DBA/2 (right) targets, equivalent blocking was 
observed with either BALB/c, DBA/2, or C.AL-20 inhibitors. 
These data indicate that at least for the three Igh haplotypes tested, that there 
is no detectable polymorphism of this gene. 
CTL Recognize an H Antigen Controlled  by a Gene Linked in or Near Igh-C and 
Their Specificity Is Further Restricted  by H-2.  We (12) previously demonstrated FORMAN  ET  AL.  1727 
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FIGURE  1.  CTL recognize H-40, an antigen controlled by an Igh-linked gene. C.B-20 anti- 
BALB/c (A-C), BALB/c anti-C.B-20 (D), or B10.Q anti-BALB/c (E-H) CTL  were tested 
against the following LPS splenic lymphoblast target cells. Q, BALB/c; O, BAB-14; x, C.AL- 
20; V, (C.B-20  ×  C57L/J)FI; T, (C.B-20  × C58/J)Fn;  +, C.B-20;  *, NZB. Data expressed as 
net isotope release. 
that C.B-20 anti-BALB/c CTL recognize a target antigen controlled by a gene 
near the constant region (Igh-C) side of the Igh locus. Rolink et al. (22) reported 
that BALB/c anti-C.B-20 recognized 2  minor H  antigens, one controlled by a 
gene linked on  the Igh-C side,  the other linked on  the Igh-V side of the Igh 
complex. Although these antigens appear to be different than the one described 
here and previously (11,  12),  we tested the specificity of BALB/c anti-C.B-20 
CTL. 
BALB/c anti-C.B-20  CTL lysed C.B-20  LPS lymphoblasts, as expected (Fig. 1728  CYTOTOXIC  T  LYMPHOCYTE  RECOGNITION  OF  H-40 
TABLE  I 
Strain Distribution of the CTL Target Antigen Controlled by an Igh-Linked Gene 
Target cells 
BALB/c  C.B-20  NZB  C58"  C57L  CBA/J  DBA/2  AKR  A/J 
Igh haplotype..,  a  b  n  a  a  v  c  d  e 
Effector cells 
C.B-20 
anti-BALB/c  +*  -  -  -  +  -  +  +  - 
BALB/c 
anti-C.B-20  -  +  - 
Effector cells were tested against splenic LPS lymphoblasts. 
* Since the CTL are H-2 restricted (see Fig.  3), non H-2  a strains were  mated to C.B-20 (H-U) and 
the F, cells were used as targets. 
* Indicates net isotope release ranged between  15-40%;  -  indicates net isotope release was <5%. 
All target cells were concomitantly tested with anti-H-2  d CTL and were equally sensitive to lysis. 
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FIGURE  2.  Evidence for limited polymorphism of H-40.  C.B-20 anti-BALB/c effector cells 
4  were tested for their ability to lyse 10  BALB/c (left), C.AL-20 (center), or DBA/2 (right) LPS 
lymphoblasts in the presence of unlabeled inhibitor cells. Inhibitor cells were LPS lymphoblasts 
from O, C.B-20; Q, BALB/c; X, C.AL-20; or T, DBA/2 animals. Net release was 31, 26, and 
26 from BALB/c, C.AL-20, and DBA/2 target cells, respectively, in the absence of inhibitor 
cells at E/T =  100. Percent inhibition =  I  -  Net release of isotope in the presence of inhibitor 
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FIGURE 3.  BALB/c anti-C.B-20 CTL recognize an antigen controlled by a  gene linked to 
Igh-C and their specificity is restricted by a D-end 1-1-2  gene. (A-C) BALB/c mice were primed 
with C.B-20 spleen cells in vivo. Three  months  later their spleen cells were removed and 
cultured with C.B-20 (O), BAn-14 (x), or C.B/R3 (0) stimulator cells.  After 5 d the effector 
cells generated were tested against LPS splenic lymphoblast target cells from C.B-20 (A), BAn- 
14 (B), or C.B/R3 (C) animals. (D-G) Effector cells were generated as described above and 
tested against LPS lymphoblasts from B10.D2 (D), BI0.D2(R107) (E), B10.D2(R103) (F), and 
C57BL/10(B10) (G) animals. 
3A). However, they also lysed BAn-14 (B) but not C.B/R3 target cells (C). Since 
BAB-14 shares constant region genes and C.B/R3 shares variable region genes 
with C.B-17 (and C.B-20, see Table II), this indicates that the gene controlling 
the target antigen maps to or near the Igh-C genes, concordant with our previous 
data  using C.B-20  anti-BALB/c CTL (12).  This  is  further supported by  the 
finding that BALB/c anti-C.B-20 primed spleen cells can be restimulated in vitro 1730  CYTOTOXIC T  LYMPHOCYTE RECOGNITION OF  H-40 
with C.B-20  or BAB-14 stimulator cells but not C.B/R3  to generate CTL that 
lyse C.B-20, BAB-14, and B10.D2 (Ighb), but not C.B/R3 target cells (Fig. 3, A- 
O). 
In order to map which end of the H-2 complex controls the specificity of these 
CTL, we tested the BALB/c anti-C.B-20 CTL against B10.D2 (Igh  b) target cells 
as well as H-2 recombinant strains on the C57BL/10 background. The data in 
Fig.  3  demonstrate  that  B10.D2(R107)  cells  (H-2KbD  a)  are  lysed  while 
B10.D2(R103) (H-2KaD b) and C57BL/10 (H-2KbD  b) cells are not. This maps the 
restricting gene to the right of the S region and most likely is either H-2D and/ 
or H-2L. 
The CTL Target Antigen Is Not AUelicalty Excluded.  Allelic exclusion of lgh loci 
has been demonstrated by the finding that in heterozygotes only one of the two 
possible Igh allotypes is expressed or secreted by individual B cells (23). Presum- 
ably  this  is  due  to  inappropriate  gene  rearrangements on  the  nonexpressed 
chromosome (24). Since H-40 is linked to the Igh locus, we determined whether 
this gene is also allelicaily excluded. Because the target antigen is expressed on 
sIg  + but not sIg- cells (reference 12, and following sections), we used the FACS 
III to sort for sIgD  + cells in  (BALB/c ×  C.B-20)F1  (Igh~/Igh b) animals using a 
monoclonal anti-Igh-5  a (anti-~) antibody. The sorted cells, both bright and dull, 
as well as stained but unsorted cells were placed in culture together with LPS. 
After 3 d, the cells were harvested and used as target cells in the CTL assay. 
(BALB/c ×  C.B-20)F~  spleen cells, either untreated or treated with anti-Igh- 
5  a antibodies (but unsorted), were sensitive to lysis by the C.B-20 anti-BALB/c 
CTL (Fig.  4, left).  Although the antibody-treated, but unsorted cells were less 
sensitive to CTL-mediated lysis than were the untreated cells, this finding was 
not  observed  in  a  second  experiment.  Importantly,  the  Igh-5  ~ positive  and 
negative cells, which were sorted before culturing, were equally sensitive to lysis. 
We also monitored the different target cell populations for their sensitivity to 
lysis by anti-H-2  d effector cells (Fig. 4, right). No difference was noted. 
These  data  indicate  that  both  sets of B  lymphoblasts express  the  BALB/c 
target antigen. Therefore, there is no allelic exclusion of H-40. 
Localization of the Igh-linked Locus That Controls the CTL Target Antigen.  The 
target antigen for the C.B-20 anti-BALB[c CTL is selectively expressed on sIg  ÷ 
lymphoblasts and  tumor cells (12).  Further,  we previously demonstrated that 
while the sIg  ÷ tumor  BCL1  expressed the antigen, the BCLlX63  hybridoma, 
which secretes BCL1  Ig but is slg-, does not (12).  This correlative data would 
suggest that the CTL recognize a determinant on sIg, itself. Therefore, it would 
be predicted that the locus controlling the antigen would map in the Igh-C region. 
We utilized strains that have undergone recombination in their 12th chromosome 
in this region to address this question. 
We (12) previously showed that BALB]c but not BAB-14 target cells expressed 
the antigen recognized by C.B-20 anti-BALB/c CTL, indicating that the target 
antigen maps on the C rather than the V side of Igh. A similar result, in that they 
did not lyse lymphoblasts from the C.B]R3 strain which shares the V but not C 
region  of Igh  with  C.B-20  (Fig.  3C,  see  Table  II  for  strain  genotypes) was 
observed using BALB/c anti-C.B-20 CTL. A further analysis was carried out on 
a series of Igh recombinant strains using C.B-20 anti-BALB/c effector cells. FORMAN  ET  AL.  1731 
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FIGL~gZ 4.  H-40 is not allelically excluded. (BALB/c x  C.B-20)F~  spleen cells were  sorted 
for sigh-5  a positive or negative cells using the FACS llI.  The cells were cultured with LPS 
and used 3 d  later as target cells in the presence of C.B-20 anti-BALB/c (left) or B10.Q anti- 
BALB/c (right)  effectors. LPS lymphoblast target cells were untreated (O), stained but unsorted 
(V), sigh-5  ~ positive (X), or sigh-5  ~ negative (O). 
TABLE  II 
C.B/R Igh Recombinant Strains Indicate  That the Igh Locus Does Not Control the CTL 
Antigen 
Allele/Antigen  Presence of 
Strain 
Dex*  Igh  Pre-1  target antigen 
BALB/c  +  a  a  + 
C.B-17  -  b  o  - 
BAB-14  +  /'4:  b  o  - 
C.B/R3  -  /  a  a  + 
C.B/R4  -  /  a  a  + 
C.B/R6  +  /  b  o  - 
C.B/R8  +  a  /  o  - 
C.B/R9  -  b  /  a  + 
C.B/R10  -  b  /  a  + 
C.B-20 anti-BALB/c CTL were tested against LPS-stimulated splenic 
Table I. 
* Defined by idiotypic marker on anti-dextran antibodies (13). 
* Indicates region of cross-over. 
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TABLE III 
C.B.AL Igh Recombinant Strains Indicates That the Locus Controlling the Target Antigen Is 
Telomeric to Tsu 
Allele/Antigen  CTL 
Strain 
Dex  Igh-C  Tsu  d  Pre- 1  Antigen 
BAB/14  +  b  -  c  - 
C.AL-9  -  d  d  a  + 
C.B.AL/1  -  /  b  -  /  a  + 
C.B.AL/2  -  /  b  -  c  - 
C.B.AL/3  -  /  b  -  c  - 
C.B.AL/4  -  /  b  -  c  - 
C.B.AL/5  -  /  b  -  c  - 
C.B.AL/6  -  /  b  /  d  a  + 
See Table 11 for explanation. 
The  C.B/R  series  of Igh  recombinant  strains  were  derived from (C.B-17  × 
BALB/c)FI  ×  C.B-17  backcross animals.  The presence of the CTL antigen on 
strains  C.B/R3  and  C.B/R4  and  its  absence  on  BAB-14  and  C.B/R6  further 
confirm  that  the  locus  maps  to  the  right  of the  crossover  between  the  gene 
controlling the  Dex idiotype and Igh (Table lI).  Strains C.B/R8,  R9,  and R10 
have undergone recombination between the lgh and Pre-I locus. The fact that 
C.B/R8 is antigen negative but is Igh  a, whereas, C.B/R9 and C.B/R10 are Igh  b 
but express the CTL antigen, indicates that the gene maps to the right of those 
crossovers between Igh and Pre-1. 
The C.B.AL series of Igh recombinant strains were derived from (BAB-14 × 
C.AL-9)FI ×  C.AL-9 backcross animals.  It is apparent from the testing of these 
strains  (Table  III)  that  the  CTL  locus  again  maps  with Pre-l.  C.B.AL/4  and 
C.B.AL/5 strains are negative for the antigen, indicating that the locus maps to 
the right of the Dex idiotypic marker.  Further,  the finding that the C.B.AL/1 
strain expresses the antigen but does not carry the Tsu d allele indicates that the 
gene maps to the right of the Tsu locus. 
Taken together, these data indicate that a gene that maps distal to Igh and, as 
of yet unseparated from Pre-1, controls an antigen selectively expressed on sIg  + 
cells and recognized by CTL. Further,  in the accompanying report we demon- 
strate that  this antigen  elicits tumor rejection in allotype congenic recipients. 2 
We have termed this gene H-40. 
Expression  of the CTL Antigen  on  B Lymphomas.  We  previously showed that 
the CTL antigen is expressed on sIg  ÷ LPS stimulated splenocytes, but not sIg- 
Con A-stimulated splenocytes (12). Further, an analysis of a variety of myelomas, 
T  cell  tumors,  and  BCL~,  the  sIg  +  BALB/c tumor,  indicated  that  only BCL, 
expressed  the  target  antigen.  The  availability  of a  further  number  of  sIg  + 
lymphomas has now allowed us to extend these studies. 
Six B lymphomas were tested for the presence of H-40 (Table IV). The only 
lines that  were positive for the  antigen  were subclones of BALENLM17;  viz., 
Henderson, L., R. Ciavarra, R. Riblet, andJ. Forman. 1984. H-40, an antigen controlled by an 
Igh-linked gene and recognized by cytotoxic T  lymphocytes. II. Recognition of H-40 as a tumor 
antigen in leukemic animals. Submitted for publication. FORMAN ET  AL. 
TABLE IV 
Sensitivity of slg  + B Lymphoma Cells to Lysis by Anti-Igh CTL 
1733 
Relative 
Experi-  Tumor*  Strain  lg isotype  slg  Cell type  Net 
ment  expres-  release  I 
sion~ 
ABE-8  BAL8/c  ~,  --  Pre-B lymphoma  0(42) 
WEHI-231  (BALB/c x  NZB)Ft  #,,x  m  B lymphoma  3(51) 
2PK3  BALB/c  "t'h,~  1  B lymphoma  0(51) 
--  BALB/c  LPS splenic  42(38) 
lymphoblasts 
A20-056  BALB/c  t~,Th,x,~  I  B lymphoma  5(32) 
M 12  BALB/c  K  B lymphoma  3(26) 
BALEN LM 17.1.11.15  BA LB/c  #,x,~  h  B lymphoma  34(29) 
BALEN LM 17.1.1  I. 16  BALB/c  t~,K,~  h  B lymphoma  33(32) 
B 17 *  BA  LB/c  t~,~,~  h  B lymphoma  21 (31 ) 
--  BALB/c  LPS splenic  38(31) 
lymphoblasts 
3  Meth A  BALB/c  Fibrosarcoma  1  (19) 
--  BALB/c  LPS splenic  32(33) 
lymphoblasts 
* Tumors in Experiment I  were obtained from Dr. L. Lanier, those in Experiment 2 were derived by Asofsky and co-workers (17) 
and provided to us by Drs. C. Word and M. Kuehl, and those in Experiment 3 from Dr. E. Stockert (see Methods and Materials). 
The B 17* tumor is a variant of BALENLM 17 (M. Kuehl, personal communication). 
Data taken from references 16-18. 
! Net release at E/T =  100.  Numbers in parentheses represent net release using anti-H-2  d CTL at E/T =  100. 
BALENLM 17-1.11.15,  16, and B 17". These subclones express a relatively high 
concentration of sIg (17). Although H-40  ÷ cells express sIgM, a putative precur- 
sor  of the  sIgM  + cell  represented  by the  pre-B  lymphoma,  ABE-8,  does  not 
express the antigen. Meth A tumor cells have been reported to express an antigen 
controlled  by a  gene  on  the  12th  chromosome  that  interacts  with  a  T  cell- 
derived suppressor factor (25).  However, this tumor does not express the CTL 
target antigen. The presence of sIgM does not ensure expression of the antigen, 
since  WEHI231,  a  tumor  that  has  a  high  density  of sIgM  by FACS  analysis 
(reference 26, and data not shown), does not express the antigen.  The fact that 
the tumor is derived from a (BALB/c ×  NZB)F1 animal where one parent (NZB) 
is antigen negative cannot account for this result, since we showed that there is 
no allelic exclusion of H-40 (see Fig. 4). 
Recently, the in vitro adapted  BCLI line described by Gronowicz et at.  (27) 
was  subcloned  (21).  Two  of the  subclones,  3G2  and  3B3-10,  were  sIg  ÷  as 
demonstrated  by  FACS  analysis  (Fig.  5).  Two  other  subclones,  B1.4.23  and 
B1.4.24, are sIg- (data not shown). We tested these four subclones, the parent 
BCL1  tumor,  as  well  as  the  sIg-  secreting  hybridoma  (BCL1X63),  which  was 
produced by fusing BCL1  to  MOPC21  myeloma cells,  for the presence of the 
CTL antigen.  In these experiments both bulk-cultured CTL and a  CTL clone 
with specificity for H-40 were used to test for the presence of the antigen.  The 
CTL  clone  has  the  same  specificity as  the  bulk-cultured  CTL  and  lyses  LPS 
cultured  B  lymphoblasts  but  not  Con  A-cultured  T  lymphoblasts  (data  not 
shown). 
Both the CTL clone and the bulk-cultured effector cells lysed BCL~  but not 
the slg- (BCLX63) hybridoma, as we previously observed (12) (Fig. 6). The CTL 1734  CYTOTOXIC  T  LYMPHOCYTE  RECOGNITION  OF  H-40 
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FIGURE 5.  Expression of sIg on two subciones of BCL~. 3B3-10 (top) or 3G2 (bottom) cells 
were stained by indirect immunofluorescence using rabbit anti-~ (solid lines) or normal rabbit 
serum (dashed lines) and analyzed with the  FACS III.  The fluorescent gain  was set at  2. 
10,000 cells were analyzed. 
clone and the bulk-cultured cells also lysed the 3G2 and 3B3-10, but not the 
B1.4.23 and B1.4.24 targets. Thus, in agreement with our previous report (12) 
and the data presented here (Table  IV),  sIg- cells  do not express the target 
antigen. We have attempted to block the CTL clone from recognizing the target 
antigen on BCLI and 3B3 cells with rabbit antibody directed against the BCL~ 
idiotype. However, these experiments have yielded negative results (data  not 
shown). 
Taken together, the above data show that only sIg- cells (presumably sIgM) 
express H-40. However, the structural gene that encodes this antigen is not an 
immunoglobulin gene. FORMAN  ET  AL.  1735 
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FIGURE  6.  Expression of H-40  on subclones of BCL].  C.B-20 anti-BALB/c bt/lk  cultured 
(right) or cloned (left) CTL were tested for their lytic potential against the sIg  + BCL1 leukemia 
(V), slg- BCL]X63  hybridoma cells (O) and 4  BCL~  subclones. Two of the subclones were 
sIg  +, 3G2 (O) and 3B3-10 (*), and two were sIg-, BI.4.23 (V) and B1.4.94 (×). 
Discussion 
The  data  in  this  report  define an  Igh-linked  minor  H  (histocompatibility)  - 
gene, H-40, which maps telomeric to the Tsu locus in the region of Pre-I.  This 
gene controls an antigen,  H-40, which is detected in vitro by CTL and in vivo 
by tumor rejection (11, 25). We (12) previously noted that sIg  + LPS but not sIg- 
Con  A  splenic  lymphoblasts  were  sensitive  to  lysis  by  either  C.B-20  anti- 
BALB/c or BALB/c anti-C.B-20  CTL.  The  same result occurs when analyzed 
with C.B-20 anti-BALB/c CTL clones (data not shown). Further, we (12) showed 
that the sIg  + leukemia, BCL] (#,~), expressed this antigen while sIg- tumor cells 
including a  hybridoma (produced by fusing BCL] to a  myeloma) that  secreted 
the BCL~  IgM, several myelomas, and a  T  cell leukemia did not express H-40. 
Thus, H-40 is preferentially, if not exclusively, expressed on sIg  + cells. 
In the present  study we have extended this phenotyping using a  panel  of B 
lymphomas. Our results revealed that in addition to BCLb other sIg  ÷ B lympho- 
mas also express H-40.  Detection of the CTL antigen  was correlated  with the 
expression of a  relatively high density of sIg on these tumor cells. The finding 
that  2PK3  (7~a,) and  A20-056  (#,7~a)  were  not  sensitive  to  lysis  while  the 
BALENLM17 subclones BALENLM17.1.11.15,  16 (#), BI7* (#), and BCL] (#6) 
were, suggests that the antigen is expressed on cells that are sIgM  +. Conversely, 
tumors with little or no detectable slg were not killed. This included ABE-8 (a 
pre-B lymphoma), A20-056 and  M12 (B lymphomas), and  Meth A  (a fibrosar- 
coma).  This  latter  tumor  has  been  reported  to  express  an  antigen  that  is 
controlled by a gene on the  12th chromosome and that interacts with a T  cell- 
derived suppressor factor (25). 1736  CYTOTOXIC T  LYMPHOCYTE RECOGNITION OF  H°40 
An exception to the correlation  between the coordinate expression of sIgM 
and  H-40 was the findings with WEHI231.  This  lymphoma (u) has a relatively 
high sIg density, but is not sensitive to CTL-mediated lysis. Whether this result 
indicates that WEHI231  has an aberrant form of sIg or that there is a require- 
ment for a factor in addition to sIg for H-40 expression cannot be determined 
at this time. 
We (21) recloned the  in  vitro BCL tumor line of Gronowicz et al.  (27) and 
tested  four  subclones  for  the  presence  of H-40.  Two  of the  (sIg  ÷)  subclones 
expressed the antigen, as detected by both bulk culture and cloned CTL, while 
two other (sIg-) subclones were H-40 negative. Thus, this data suggests that the 
expression of the antigen is strictly dependent on a sIg positive phenotype, even 
though the gene controlling this antigen is separable from the Igh gene cluster. 
It should be noted that our ability to detect H-40 is limited by the sensitivity 
of the CTL assay. Thus, it is possible that some of the cell populations that we 
describe as H-40- may, in fact, express this  molecule.  However, even if this is 
the case,  it  is still  evident that  the relative  expression  of H-40 on sIg  + cells is 
much greater than that on sIg- cells. 
The construction of strains that are genetically recombinant in the region of 
the Igh locus enabled us to map the gene controlling this antigen. Using different 
sets of Igh recombinant strains we showed that H-40 maps away from the genes 
(Igh)  that  encode Ig heavy chains.  This  indicates  that  although  the antigen  is 
expressed on sIg  ÷ positive cells, it is not controlled by an immunoglobulin heavy 
chain (Igh) structural gene. We further demonstrated that H-40 maps telomeric 
to Tsu and as of yet is unseparated from Pre-1.  This makes the gene order Igh- 
V, Igh-C, Tsu, H-40/Pre-1. H(Igh) maps to the C-region side of the Igh complex 
(9).  We are  currently  in  the  process of determining  the  relationship  between 
H (  Igh ) and H-40. 
There  are  several possibilities to explain  the coordinate  expression  of H-40 
with slg.  Firstly, this finding could be coincidental. Thus, Tyler et al. (28) have 
described  a  minor  H-gene  that  controls  a  CTL  target  antigen  that  is  also 
preferentially expressed on sIg  + cells. Since B10.K and AKR animals share the 
same allele for this  alloantigen  (D.  Steinmuller,  personal  communication)  it  is 
unlikely that this antigen is controlled by H-40, since we have shown that these 
strains have different H-40 alleles.  Secondly, the fact that the detection system 
(CTL)  is  relatively  insensitive  in  that  only certain  cell  types can  be used  in  a 
standard  CTL assay biases the results in  favor of lymphoblasts over other cell 
types. Accordingly, if additional cell types could be tested they might be found 
to  be  H-40  +.  Thirdly,  the  CTL  antigen  could  be  sIg  even  though  the  gene 
controlling it maps to a locus that is distinct from the Igh cluster. One possibility 
is that H-40 is an enzyme that posttranslationally modifies sIg. Eidels (29) noted 
that sIgD could be expressed as  ¢~2L2 or 6L. Pollock et al. (30) noted an allotype- 
linked genetic variation  in the relative expression of these two different forms 
of sIgD. Taken together, these findings suggest that an Igh-linked gene controls 
the subunit structure  of sIgD.  Thus,  it is possible that  in an analogous fashion 
there  is a  variant  of sIgM  that  accounts  for  the  H-40 epitope.  In  a  different 
system, Huber (31) has defined an epitope, Iaw.39, which is expressed on the I- 
A b molecule. This epitope is not found in (CBA/N ~  x  C57BL/6 ~)Fl animals, FORMAN  ET  AL.  1737 
even  though  they possess  a  normal  LA b gene.  Apparently a  gene  on  the  Y 
chromosome and missing in the CBA/N mouse controls the expression of this 
particular specificity on I-A  b. Another possibility to explain these findings is that 
the antigen recognized by CTL represents a determinant formed by the inter- 
action of two  gene products;  i.e.,  sIgM  and  the molecule encoded by Ho40. 
According to this model, these two molecules would interact with an H-2 class I 
molecule to form a tri-molecular species containing the alloantigen. 
Irrespective of the lgh  haplotype,  we noted that  the presence of the  CTL 
antigen  was  determined solely by a  gene (H-40)  that  maps  to  the region  of 
Pre-l. Thus, if H-40 modifies sIg to create the CTL epitope, then sIg from either 
the Igh  a or Igh  b haplotype can be the substrate. This interpretation would also be 
consistent  with  our  data  showing  that  the  expression  of the  antigen  is  not 
allelically excluded in heterozygous B cells. 
If the expression of this  antigen  is  coincidental with  the expression of sIg 
rather  than  representing an  epitope  on  sIg,  itself,  then  it  is  possible  that  it 
represents  an  allelic  variant  of a  receptor  for  a  differentiation  signal  of B 
lymphocytes. For example, the finding that it is found on sIgM but not sIgG cells 
could make it a candidate for a B cell differentiation factor that potentiates the 
expression of a particular class of Ig (32). 
We were unable to block lysis of target cells using anti-Ig antibodies. While 
this would suggest that the target antigen is not sIg, there are many examples in 
CTL systems where the target antigen is not masked by antibody directed against 
the antigen (33, 34). Therefore, this issue is still open at this time. 
In contrast to the previous report of Rolink et al.  (22),  who described two 
CTL  target antigens controlled by genes linked to  the Igh  locus,  we did not 
detect an antigen controlled by a gene in the V-region of the Igh complex, nor 
did we note the antigen expressed on sIg- cells. We have generated our CTL 
using C.B-20 anti-BALB/c (and vice-versa) effector cells. The above investigators 
generated CTL  with C.B-17  and BALB/c cells.  The BALB/c mice they used 
were from a different source than the Potter stock used in this study. Therefore, 
it is possible that additional lgh-linked genes with allelic variation control antigens 
that are immunodominant with respect to H-40 and were defined by Rolink et 
al.  (22).  Further, since there is a  difference in Qa-2 alleles between BALB/c 
sublines which can give rise to anti-Qa-2 CTL (35), it cannot be ruled out that 
the C.B-17 anti-BALB/c reactivity that they described was directed against the 
Qa-2  a antigen. 
The tissue distribution of most minor H-antigens is not known. Steinmuller et 
al. (36) have described a lymphocyte and a skin-specific minor H antigen. Carter 
and Wegman (37) noted an antigen detected by CTL in the spleen but not in 
the thymus. In this and a  previous communication (12) we have described an 
antigen expressed on sIg  + cells. Since in most cases minor H  antigens are only 
detected by graft rejection or cell-mediated cytolysis rather than with serological 
reagents, the tissue distribution and further characterization of these molecules 
awaits clarification. 
In an upcoming paper  2 we describe how H-40 acts as a tumor rejection antigen 
on BCL~ tumor cells when injected into Igh congenic recipients. 1738  CYTOTOXIC T  LYMPHOCYTE RECOGNITION  OF  H-40 
Summary 
C.B-20 (Igh b) mice challenged with BALB/c (Igh a) spleen cells (or vice-versa) 
generate  cytotoxic  T  iymphocytes  (CTL)  that  recognize  an  antigen,  H-40, 
controlled by an Igh-linked gene. The gene maps to the Igh-C region end of the 
Igh complex, telomeric to Tsu in the region of Pre-1.  At least three alleles, a, b, 
and c, can be defined. Using a  cold target competition assay, no polymorphism 
of the a allele was detected. Both surface Igh-5  a positive and negative spleen cells 
from (C.B-20 X BALB/c)F1 animals express the a allele of the antigen, indicating 
that  this gene is not allelically excluded.  Recognition of the  target antigen  by 
CTL is restricted by the D-end of H-2 ~. 
The tissue  distribution  of H-40  was  explored using  both bulk-cultured  and 
cloned CTL. The antigen is expressed on surface immunoglobulin positive (sIg  +) 
cells and correlates with the expression of sIgM. This was determined by analysis 
of several B lymphomas as well as of other tumors that varied in their extent of 
expression of sIg. Four subclones of BCL~ were analyzed. Two of the subclones 
are sIg  + and express H-40, while two other subclones are sIg- and H-40-. Thus, 
these data define an Igh-linked gene, separate from immunoglobulin structural 
loci,  that  controls an  antigen  expressed on  sIg  + cells.  Possible  mechanisms  to 
account for this finding are discussed. 
We would like to acknowledge the expert technical assistance ofJ. Tsan and S. Byers, and 
B.J. Washington for her secretarial assistance. 
Received  for publication 30January  1984. 
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